Shanghai RAAS Blood Products Co., Ltd.
002252
Rang in aandelen
#3647
Shanghai RAAS Blood Products Co., Ltd. engages in the research, development,... Shanghai RAAS Blood Products Co., Ltd. engages in the research, development, production, and sale of blood products. It provides human albumin, intravenous injection of human immunoglobulin, coagulation factor products, vaccines, diagnostic reagents, and testing services. The company was founded by Kieu Hoang on October 29, 1988 and is headquartered in Shanghai, China.
Aandeelprijs
$0.70283234
Marktkapitalisatie
$4.63B
Verandering (1 dag)
-0.61%
Verandering (1 jaar)
-25.18%
Land
CN
Handel Shanghai RAAS Blood Products Co., Ltd. (002252)
Categorie
Healthcare
Winst voor Shanghai RAAS Blood Products Co., Ltd. (002252)
Winst in Jun 2026 TTM: $217.03M
Volgens de meest recente financiële verslagen van Shanghai RAAS Blood Products Co., Ltd. bedraagt de huidige winst van het bedrijf $217.03M. In 2023 behaalde het bedrijf een winst van $311.37M, een daling ten opzichte van de winst van 2022, die $329.61M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Shanghai RAAS Blood Products Co., Ltd. van 2005 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $217.03M | -39.54% |
| 2024 | $358.96M | 15.28% |
| 2023 | $311.37M | -5.53% |
| 2022 | $329.61M | 36.12% |
| 2021 | $242.14M | 7.08% |
| 2020 | $226.13M | 114.78% |
| 2019 | $105.29M | -141.25% |
| 2018 | $-255.27M | -265.29% |
| 2017 | $154.43M | -45.28% |
| 2016 | $282.21M | 4.77% |
| 2015 | $269.37M | 177.16% |
| 2014 | $97.19M | 248.88% |
| 2013 | $27.86M | -34.34% |
| 2012 | $42.43M | 13.57% |
| 2011 | $37.36M | 11.62% |
| 2010 | $33.47M | 43.19% |
| 2009 | $23.37M | 28.12% |
| 2008 | $18.24M | 35.94% |
| 2007 | $13.42M | 74.83% |
| 2006 | $7.68M | 1.12% |
| 2005 | $7.59M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | 2,330.53% |
US
|
|
| $-3.09B | -1,522.40% |
US
|
|
| $-4.02B | -1,950.55% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 798.81% |
NL
|
